Breaking News

Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

Satsuma Pharmaceuticals Thursday, June 16th @ 10:30 a.m. ET SOUTH SAN FRANCISCO, Calif., June 07, 2022 (World NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a medical-stage biopharmaceutical organization developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic products candidate for the acute remedy of migraine, these days introduced that it will host a Essential […]